ARCHIVE

Shionogi to Acquire 9 Products from Victory Pharma of the US

August 1, 2011
Shionogi & Co. announced on July 19 that its US subsidiary Shionogi Inc. will acquire US marketing rights to all nine products of Victory Pharma, Inc. including seven pain treatments and two treatments for infectious diseases. By bolstering Shionogi's product…

To read the full story

ARCHIVE

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

By Philip Carrigan

The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…

By Shinya Sato

As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

By Ken Yoshino

The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…